Bioxiness Pharmaceuticals

Bioxiness is developing a novel class of antimicrobial compounds with a new mode of action for the treatment of severe bacterial infections.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Hercules, CA, USA
  • Currency USD
  • Founded October 2007
  • Employees 3
  • Website bioxiness.com

Company Summary

Bioxiness is developing a new class of antimicrobial compounds that can potentially be used against the fight in combating drug resistant pathogens - with an emphasis on gram-negative bacteria. The company is using a novel technology platform and has very encouraging data. Its IP has advanced to the international filing stage.

Team

  • Richard Gless
    Head of Chemistry

  • Mansour Bassiri
    CEO

  • Reza Ilkhani
    CFO

  • Paul Luciw
    Chair, Scientific Advisory Baord

  • Clint Severson
    Board Member

  • Reza Ilkhani

Advisors

  • Morrison & Foerster
    Lawyer
    Unconfirmed
    RoseRyan
    Accountant
    Unconfirmed

Previous Investors

  • Individual accredited investors
    Unconfirmed
    (incl. a large pharma retired scientist with antibiotic background)
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free